Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cabaletta Bio, Inc. before investing.

In this article, we go over a few key elements for understanding Cabaletta Bio, Inc.’s stock price such as:

• Cabaletta Bio, Inc.’s current stock price and volume
• Why Cabaletta Bio, Inc.’s stock price changed recently
• Upgrades and downgrades for CABA from analysts
• CABA’s stock price momentum as measured by its relative strength

About Cabaletta Bio, Inc. (CABA)

Before we jump into Cabaletta Bio, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Want to learn more about Cabaletta Bio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cabaletta Bio, Inc..

Cabaletta Bio, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Cabaletta Bio, Inc.’s stock price was $2.680.

Cabaletta Bio, Inc. is down 1.47% from its previous closing price of $2.720.

During the last market session, Cabaletta Bio, Inc.’s stock traded between $2.600 and $2.720. Currently, there are approximately 112.03 million shares outstanding for Cabaletta Bio, Inc..

Cabaletta Bio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cabaletta Bio, Inc. Stock Price History

Cabaletta Bio, Inc.’s (CABA) price is currently down 13.83% so far this month.

During the month of July, Cabaletta Bio, Inc.’s stock price has reached a high of $3.330 and a low of $2.590.

Over the last year, Cabaletta Bio, Inc. has hit prices as high as $4.230 and as low as $1.260. Year to date, Cabaletta Bio, Inc.’s stock is up 22.37%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cabaletta Bio, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Cabaletta Bio, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cabaletta Bio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cabaletta Bio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cabaletta Bio, Inc. (CABA) by visiting AAII Stock Evaluator.

Relative Price Strength of Cabaletta Bio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Cabaletta Bio, Inc. has a weighted four-quarter relative price strength of 7.82%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how Cabaletta Bio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cabaletta Bio, Inc. Stock Price: Bottom Line

As of July 31, 2026, Cabaletta Bio, Inc.’s stock price is $2.680, which is down 1.47% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cabaletta Bio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.